Teemu J Taipale1, Kaisu Pienihäkkinen2, Erika Isolauri3,4, Jorma T Jokela1, Eva M Söderling2. 1. Korpilahti-Muurame Health Care Center, Muurame, Finland. 2. Institute of Dentistry, University of Turku, Turku, Finland. 3. Department of Paediatrics, University of Turku, Turku, Finland. 4. Turku University Hospital, Turku, Finland.
Abstract
BACKGROUND:Specific probiotic bacteria have proven to be effective in the prevention and treatment of infectious diseases in early life in at-risk populations. The impact of administration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on the risk of acute infectious diseases was studied in healthy children. METHODS: In this double-blind, placebo-controlled study, 109 1-mo-old infants were assigned randomly to a probiotic group receiving a BB-12-containing tablet (n = 55) or a placebo (n = 54). Test tablets were administered to the infants twice a day (daily dose of BB-12 10 billion colony-forming units) until the age of 2 y with a novel slow-release pacifier or a spoon. Breastfeeding habits, pacifier use, dietary habits, medications, and all signs and symptoms of acute infections were registered in diaries by parents and in questionnaires by trained professionals. RESULTS: The infants receiving BB-12 were reported to have experienced fewer respiratory tract infections (RTIs; 87 vs. 100%; risk ratio: 0.87; 95% confidence interval: 0.76, 1.00; P = 0.033) than the controls. No significant differences between the groups were observed in reported gastrointestinal symptoms, otitis media, or fever. The baseline characteristics of the two groups were similar, as was the duration of breastfeeding. CONCLUSION: Administration of BB-12 in early childhood may reduce RTIs.
RCT Entities:
BACKGROUND: Specific probiotic bacteria have proven to be effective in the prevention and treatment of infectious diseases in early life in at-risk populations. The impact of administration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on the risk of acute infectious diseases was studied in healthy children. METHODS: In this double-blind, placebo-controlled study, 109 1-mo-old infants were assigned randomly to a probiotic group receiving a BB-12-containing tablet (n = 55) or a placebo (n = 54). Test tablets were administered to the infants twice a day (daily dose of BB-12 10 billion colony-forming units) until the age of 2 y with a novel slow-release pacifier or a spoon. Breastfeeding habits, pacifier use, dietary habits, medications, and all signs and symptoms of acute infections were registered in diaries by parents and in questionnaires by trained professionals. RESULTS: The infants receiving BB-12 were reported to have experienced fewer respiratory tract infections (RTIs; 87 vs. 100%; risk ratio: 0.87; 95% confidence interval: 0.76, 1.00; P = 0.033) than the controls. No significant differences between the groups were observed in reported gastrointestinal symptoms, otitis media, or fever. The baseline characteristics of the two groups were similar, as was the duration of breastfeeding. CONCLUSION: Administration of BB-12 in early childhood may reduce RTIs.
Authors: Colin Hill; Francisco Guarner; Gregor Reid; Glenn R Gibson; Daniel J Merenstein; Bruno Pot; Lorenzo Morelli; Roberto Berni Canani; Harry J Flint; Seppo Salminen; Philip C Calder; Mary Ellen Sanders Journal: Nat Rev Gastroenterol Hepatol Date: 2014-06-10 Impact factor: 46.802
Authors: Stephen J Allen; Susan Jordan; Melanie Storey; Catherine A Thornton; Michael Gravenor; Iveta Garaiova; Susan F Plummer; Duolao Wang; Gareth Morgan Journal: J Nutr Date: 2010-01-20 Impact factor: 4.798
Authors: Martin H Floch; W Allan Walker; Stefano Guandalini; Patricia Hibberd; Sherwood Gorbach; Christina Surawicz; Mary Ellen Sanders; Guadalupe Garcia-Tsao; Eamonn M M Quigley; Erika Isolauri; Richard N Fedorak; Levinus A Dieleman Journal: J Clin Gastroenterol Date: 2008-07 Impact factor: 3.062
Authors: Jenni Rosendahl; Saara Valkama; Elisa Holmlund-Suila; Maria Enlund-Cerullo; Helena Hauta-Alus; Otto Helve; Timo Hytinantti; Esko Levälahti; Eero Kajantie; Heli Viljakainen; Outi Mäkitie; Sture Andersson Journal: JAMA Pediatr Date: 2018-07-01 Impact factor: 16.193
Authors: Anna M Scott; Justin Clark; Blair Julien; Farhana Islam; Kristian Roos; Keith Grimwood; Paul Little; Chris B Del Mar Journal: Cochrane Database Syst Rev Date: 2019-06-18
Authors: Rachael Lappan; Kara Imbrogno; Chisha Sikazwe; Denise Anderson; Danny Mok; Harvey Coates; Shyan Vijayasekaran; Paul Bumbak; Christopher C Blyth; Sarra E Jamieson; Christopher S Peacock Journal: BMC Microbiol Date: 2018-02-20 Impact factor: 3.605